ZS Pharma

Vifor Pharma Group is hopeful that its hyperkalemia therapy Veltassa, which enjoyed strong sales growth in 2019, will be able to fend off competition from AstraZeneca PLC 's rival treatment Lokelma.

Relay Therapeutics has raised $520m in venture capital since 2016, including a $400m Series C round announced on Dec. 20, without relaying a lot of information publicly about how it will translate it

AstraZeneca PLC is working to balance its fast-growing oncology portfolio against other priority therapy areas, which include a new specialty in renal disease. The company's oncology portfolio has gr

Pfizer Inc. 's commitment of an additional $600m to its corporate venture capital fund includes a plan to spend 25% on neuroscience investments – a curious move considering the company's decision at t